Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs

American Journal of Veterinary Research

Volumn 63, Issue 12, 2002, Pages 1622-1628

  Bidgood, Tara ^a   Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; PLASMA PROTEIN;

ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DOG; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; EXTRAVASCULAR SPACE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTERSTITIAL FLUID; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TIME; TISSUE WATER; ULTRAFILTRATION; URINALYSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036906489     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1622     Document Type: Article

References (52)

1. Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999;11:93-100.
2. Labia R, Morand A, Tiwari K, et al. Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother 1989;24(suppl A):219-223.
3. Nadler HL, Pitkin DH, Sheikh W The postantibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother 1989;24(suppl A):225-231.
4. Sanders CC, Sanders WE Jr, Thomson KS, et al. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother 1989; 24(suppl A):187-196.
5. Yang YJ, Livermore DM. Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother 1989;24(suppl A):207-217.
6. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis Suppl 1995;96:5-10.
7. Kayser FH, Morenzoni G, Strassle A, et al. Activity of meropenem, against gram-positive bacteria. J Antimicrob Chemother 1989;24(suppl A):101-112.
8. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother 1989;24(suppl A):113-117.
9. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997;28:157-163.
10. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999;74:420-434.
11. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989;24(suppl A):9-29.
12. Margaret BS, Drusano GL, Standiford HC. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24(suppl A):161-167.
13. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(suppl A):1-17.
14. Quinn JP, Dudek EJ. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986;154:289-294.
15. Lynch MJ, Drusano GL, Mobley HLT. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987;31:1892-1896.
16. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995;28:275-276.
17. Mouton JW, Touzw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185-201.
18. Satake S, Yoshihara E, Nakae T. Diffusion of beta-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:685-690.
19. Voutsinas D, Mavroudis T, Avlamis A, et al. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother 1989;24(suppl A):143-147.
20. Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24(suppl A):307-309.
21. Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother 1995;39:1721-1725.
22. Schuler D. Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother 1995;36(suppl A):99-108.
23. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36(suppl A):207-223.
24. Topham JC, Murgatroyd LB, Jones DV, et al. Safety evaluation of meropenem in animals: studies on the kidney J Antimicrob Chemother 1989;24(suppl A):287-306.
25. Dagan R, Velghe L, Rodda JL, et al. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34:175-179.
26. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
27. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;1-494.
28. Prescott JF, Hanna WJB, Reid-Smith R, et al. Antimicrobial drug use and resistance in dogs. Can Vet J 2002;43:107-116.
29. Hariharan H, McPhee L, Heaney S, et al. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Can Vet J 2002;36:166-168.
30. Cooke CL, Singer RS, Jang SS, et al. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J Am Vet Med Assoc 2002;220:190-192.
31. Oluoch AO, Kim CH, Weisiger RM, et al. Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). J Am Vet Med Assoc 2001;218:381-384.
32. Normand EH, Gibson NR, Taylor DJ, et al. Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Vet Rec 2000;146:151-155.
33. Chanal C, Sirot D, Chanal M, et al. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases. J Antimicrob Chemother 1989;24(suppl A):133-141.
34. Yourassowsky E, Van der Linden MP, Lismont MJ, et al. Bactericidal activity of meropenem against Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24(suppl A): 169-174.
35. United States Pharmacopeia-National Formulary (USP 25-NF 20). Rockville, Md: United States Pharmacopeial Convention Inc, 2002;1083-1084.
36. Jones HK, Kelly HC, Hutchison M, et al. A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes. Eur J Drug Metab Pharmacokinet 1997;22:193-199.
37. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24(suppl A):311-320.
38. Heiene R, Moe L. Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review. J Vet Intern Med 1998;12:401-414.
39. Mouton JW, Michel MF. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. J Antimicrob Chemother 1991;28:911-918.
40. Christensson BA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992;36:1532-1537.
41. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994;38:151-154.
42. Van Etta LL, Peterson LR, Fasching CE, et al. Effect of ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro model. J Infect Dis 1982;146:423-428.
43. Tegeder I, Schmidtko A, Brautigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002;71:325-333.
44. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
45. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-2583.
46. Hanberger H, Nilsson LE. Retain intermittent dosing of carbapenems. Antimicrob Agents Chemother 1994;38:159-160.
47. Hanberger H, Nilsson LE, Nilsson M, et al. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991;10:927-934.
48. Bundtzen RW, Gerber AU, Cohn DL, et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
49. Renneberg J, Walder M. Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo. Antimicrob Agents Chemother 1989;33:1714-1720.
50. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 1995;96:11-16.
51. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. 2nd ed. NCCLS document M31-A2 [ISBN 1-56238-000-0]. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2001.
52. Norris CR, Williams BJ, Ling GV, et al. Recurrent and persistent urinary tract infections in dogs: 383 cases. J Am Anim Hosp Assoc 2000;36:484-492.